The company manufactures over 50 unique products from its New York facility, including tablets, caplets, capsules and pellets.

Time-Cap’s average annual revenue over the past four years is in excess of $30 million per annum, and it achieved an average annual adjusted EBITDA of approximately $4 million, it said, adding that the company currently has no debt.